CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced earnings of $0.04, delivering a surprise of 123.53%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. CytomX Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $26.61 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 13.90%. This compares to year-ago revenues of $0.95 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earni
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling [Seeking Alpha]Seeking Alpha
- CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $3.25 price target on the stock.MarketBeat
- CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024GlobeNewswire
- CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town [Seeking Alpha]Seeking Alpha
CTMX
Earnings
- 11/7/23 - Beat
CTMX
Sec Filings
- 5/1/24 - Form DEFA14A
- 4/4/24 - Form DEFA14A
- 4/4/24 - Form DEF
- CTMX's page on the SEC website